A multicenter, double-blinded, placebo-controlled, single ascending dose, two-part, randomized, phase 2 clinical trial to assess safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of BB-031 in acute ischemic stroke (AIS) patients (RAISE)

Principal Investigator

Dr James Kennedy

Contact us

Email: Rachel.teal@ouh.nhs.uk

IRAS number

1012801